- Pegfilgrastim, sold
under the
brand name
Neulasta among others, is a
PEGylated form of the
recombinant human granulocyte colony-stimulating
factor (GCSF)...
- from the
original on
February 24, 2020.
Retrieved September 9, 2020. "
Neulasta EPAR".
European Medicines Agency (EMA).
Archived from the
original on June...
- 2019)
Kyprolis (carfilzomib)
Lumakras (sotorasib)
Mvasi (bevacizumab-awwb)
Neulasta (pegfilgrastim) for
neutropenia (FDA
approved 2002)
Neupogen (granulocyte...
- Germany/United
States in 1986. The FDA
approved the
first biosimilar of
Neulasta in June 2018. It is made by
Mylan and sold as Fulphila. The recombinant...
- Granulocyte-macrophage colony-stimulating
factor receptor Lenzilumab Pegfilgrastim (
Neulasta, a
PEGylated form filgrastim) GRCh38:
Ensembl release 89: ENSG00000164400...
- parti****nts were
randomized to
receive efbemalenograstim alfa or placebo, or
Neulasta,
after receiving myelosuppressive anticancer drugs ****ociated with a clinically...
-
development stages.
Sales of the two most
successful products,
Pegasys and
Neulasta,
exceeded $5
billion in 2011. All
commercially available PEGylated pharmaceuticals...
- / NESP /
Aranesp REGPARA Oncology medicines ABSTRAL GRAN /
Peglasta /
Neulasta LEUNASE Mitomycin-C
SANCUSO Diagnostics In
vitro diagnostic reagents, analyzers...
-
recombinant granulocyte colony-stimulating factor, the
basis for
neupogen and
neulasta,
earning the
institute well over $100 million. In 2000,
former NIH director...
- 39% Sanofi-Aventis
Diabetes mellitus type 1 and 2 Apr-2000 2011-Dec 10
Neulasta Pegfilgrastim 854,508 -4.90%
Amgen Neutropenia Jan-2002 Mon-20XX 11 Copaxone...
